Crossmark

Comparison of the initial and residual speed of Amblyomma americanum kill on dogs treated with a single dose of Bravecto® Chew (25 mg/kg fluralaner) or Simparica TRIO® (1.2 mg/kg sarolaner, 24 µg/kg moxidectin, 5 mg/kg pyrantel)

Crossref DOI link: https://doi.org/10.1186/s13071-024-06600-2

Published Online: 2025-03-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Reif, Kathryn E.

Dryden, Michael W.

Normile, Dorothy M.

Kang, Qing

Herrin, Brian H.

Jesudoss Chelladurai, Jeba R. J.

Bickmeier, Naemi P.

Sutherland, Cameron J.

Beltz, Mallory S.
Funding

Funding for this research was provided by:

Merck Animal Health
License Information

Text and Data Mining valid from 2025-03-21

Version of Record valid from 2025-03-21
More Information

Article History

Received: 13 July 2024

Accepted: 26 November 2024

First Online: 21 March 2025

Declarations

:

: The present research was approved and complied with the regulations set forth by the Kansas State University Institutional Animal Care and Use Committee (IACUC #4677, approved 01/24/2022).

: Not applicable.

: K.E.R., B.H.H., and M.W.D. have received honoraria, expense reimbursement, and/or research support from several companies that manufacture parasite control products, including Merck Animal Health (Rahway, NJ, USA) and Zoetis (Parsippany-Troy Hills, NJ, USA). K.E.R., M.W.D., and D.M.N. were not involved in data collection. B.H.H. was masked throughout the study and was involved in data collection. D.M.N. is an employee of Merck Animal Health, Rahway, NJ, USA. J.R.J.J.C. is an Associate Editor of Parasites & Vectors. Q.K., N.P.B., C.J.S., and M.S.B. have no competing interests to declare.

Document is current

Any future updates will be listed below